Feb 18 (Reuters) - Supernus Pharmaceuticals SUPN.O said on Tuesday its depression treatment failed a mid-stage trial as it did not meet the main goal of reduction in depressive symptoms.
(Reporting by Christy Santhosh in Bengaluru; Editing by Alan Barona)
((Christy.Santhosh@thomsonreuters.com))